Treatment with direct oral anticoagulants (DOACs) does not lead to recurrence of venous thromboembolism in patients with cancer more often than treatment with low molecular weight heparins (LMWH). According to an American study (JAMA Intern Med. 2023;329:1924-33).
Patients with cancer have a greatly increased risk of venous thromboembolism. LMWH are…
The entire content of this article is only accessible to subscribers.
Read 3 articles FREE
Make an account. Free and without obligation.
I want 3x free
Always access to all NTvG publications?
Subscribe today!
Take the introductory subscription
€ 32.95 for 12 weeks!
I want to meet
Do you already have a subscription? login
2023-06-29 04:00:00
#DOAC #prevents #thrombosis #cancer #patients
